ImmunityBio, Inc. (IBRX)

ImmunityBio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-583.2	-416.57	-346.79	-221.85	-157.78
Depreciation & Amortization	24.62	24.19	19.12	17.89	18.17
Share-Based Compensation	49.16	40.18	57.18	2.19	3.42
Other Operating Activities	142.65	14.69	-3.93	30.05	-15.93
Operating Cash Flow	-366.76	-337.51	-274.42	-171.72	-152.11
Capital Expenditures	-30.58	-78.16	-13.07	-1.67	-4.09
Acquisitions	0	-1	0	0	-2.5
Change in Investments	0.11	127.69	-71.82	-18.14	25.14
Other Investing Activities	-	-21.23	-	-	-
Investing Cash Flow	-30.47	27.3	-84.89	-19.81	18.55
Share Issuance / Repurchase	299.72	59.89	165.93	86.98	66.61
Debt Issued / Paid	258.62	174.07	338.5	63.7	47.67
Other Financing Activities	-	-0.34	1.02	-	-
Financing Cash Flow	558.34	233.61	505.44	150.68	114.28
Exchange Rate Effect	-0.29	0.28	0.05	-0.03	-0.02
Net Cash Flow	160.82	-76.32	146.19	-40.89	-19.3
Free Cash Flow	-397.34	-415.67	-287.48	-173.39	-156.2
Free Cash Flow Margin	-63881.19%	-173196.25%	-30779.87%	-28660.00%	-7093.37%
Free Cash Flow Per Share	-0.78	-1.04	-0.74	-0.46	-0.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).